Skip to main content
See every side of every news story
Published • loading... • Updated

Shilpa CDMO invests $50 million to expand peptide manufacturing capacity

Summary by Express Pharma
The expansion will add 10 KL of SPPS reactor capacity and establish six parallel cGMP manufacturing lines to support peptide development and commercial supply
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Express Pharma broke the news on Wednesday, November 4, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal